Editorial: New GPCR targets and modulators to treat CNS disorders
Front. Mol. Neurosci.. 2022-12-06; 15:
DOI: 10.3389/fnmol.2022.1104336
Lire sur PubMed
1. Front Mol Neurosci. 2022 Dec 6;15:1104336. doi: 10.3389/fnmol.2022.1104336.
eCollection 2022.
Editorial: New GPCR targets and modulators to treat CNS disorders.
De Deurwaerdère P(1), Ponimaskin E(2), Chagraoui A(3)(4), Di Giovanni G(5)(6).
Author information:
(1)Centre National de la Recherche Scientifique, UMR 5287, Bordeaux, France.
(2)Neurophysiology, Hannover Medical School, Hannover, Germany.
(3)Différenciation et Communication Neuroendocrine, Endocrine et Germinale
(NorDic), INSERM U1239, IRIB, CHU Rouen, Rouen, France.
(4)Department of Medical Biochemistry, Rouen University Hospital, Rouen, France.
(5)Laboratory of Neurophysiology, Department of Physiology and Biochemistry,
Faculty of Medicine and Surgery, University of Malta, Msida, Malta.
(6)Neuroscience Division, School of Biosciences, Cardiff University, Cardiff,
United Kingdom.
Comment on
Editorial on the Research Topic New GPCR targets and modulators to treat CNS
disorders.
DOI: 10.3389/fnmol.2022.1104336
PMCID: PMC9763925
PMID: 36561894
Conflict of interest statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.